CLINICAL TRIALS PROFILE FOR TENORMIN

All Clinical Trials for TENORMIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00133692 ↗	INVEST: INternational VErapamil SR Trandolapril STudy	Completed	Abbott	Phase 4	1997-09-01	Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).
NCT00133692 ↗	INVEST: INternational VErapamil SR Trandolapril STudy	Completed	University of Florida	Phase 4	1997-09-01	Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).
NCT00389168 ↗	Irbesartan and Atenolol in Hypertensive Heart Disease	Completed	Bristol-Myers Squibb	Phase 2/Phase 3	1995-04-01	The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure. This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertension.Patients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks. Repeat investigations of blood pressure, structure and function of the heart and the vascular tree, and neurohormones were performed. Two control groups, consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison.
NCT00389168 ↗	Irbesartan and Atenolol in Hypertensive Heart Disease	Completed	Sanofi	Phase 2/Phase 3	1995-04-01	The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure. This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertension.Patients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks. Repeat investigations of blood pressure, structure and function of the heart and the vascular tree, and neurohormones were performed. Two control groups, consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison.
NCT00389168 ↗	Irbesartan and Atenolol in Hypertensive Heart Disease	Completed	Swedish Heart Lung Foundation	Phase 2/Phase 3	1995-04-01	The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure. This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertension.Patients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks. Repeat investigations of blood pressure, structure and function of the heart and the vascular tree, and neurohormones were performed. Two control groups, consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison.
NCT00389168 ↗	Irbesartan and Atenolol in Hypertensive Heart Disease	Completed	Karolinska Institutet	Phase 2/Phase 3	1995-04-01	The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure. This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertension.Patients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks. Repeat investigations of blood pressure, structure and function of the heart and the vascular tree, and neurohormones were performed. Two control groups, consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison.
NCT00507663 ↗	Elder Surgery - Functional Recovery Following Beta Blockade	Completed	National Institute on Aging (NIA)	Phase 4	2002-09-01	This study proposes a prospective randomized study of elders undergoing elective major abdominal surgery to assess recovery following a unique anesthetic regimen incorporating a adrenergic receptor antagonist. The purposes of this study are to: 1. to determine if using atenolol, a beta-blocker drug commonly used to treat high blood pressure and heart disease, as part of your anesthetic regimen will decrease complications that sometimes occur in elderly patients who are undergoing surgery and being given anesthesia. 2. to see if it improves or quickens your recovery from anesthesia and surgery. 3. to help investigators design better ways to administer anesthesia during surgery, especially in elderly patients, so that the complications and the time to recover from surgery and anesthesia can be decreased.

Clinical Trial Conditions for TENORMIN

Condition Name

Condition Name for TENORMIN
Intervention	Trials
Hypertension	3
Healthy	2
Marfan Syndrome	2
Atrial Fibrillation	2

Condition MeSH

Condition MeSH for TENORMIN
Intervention	Trials
Hypertension	3
Syndrome	2
Marfan Syndrome	2
Pre-Eclampsia	2

Clinical Trial Locations for TENORMIN

Trials by Country

Trials by Country for TENORMIN
Location	Trials
United States	26
Canada	1
Sweden	1
Korea, Republic of	1

Trials by US State

Trials by US State for TENORMIN
Location	Trials
Tennessee	3
Minnesota	3
Georgia	2
Massachusetts	2
Florida	2

Clinical Trial Progress for TENORMIN

Clinical Trial Phase

Clinical Trial Phase for TENORMIN
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for TENORMIN
Clinical Trial Phase	Trials
Completed	9
Unknown status	4
Withdrawn	1

Clinical Trial Sponsors for TENORMIN

Sponsor Name

Sponsor Name for TENORMIN
Sponsor	Trials
Emory University	2
Mayo Clinic	2
University of Florida	2

Sponsor Type

Sponsor Type for TENORMIN
Sponsor	Trials
Other	21
Industry	12
NIH	1

TENORMIN Market Analysis and Financial Projection

Last updated: April 25, 2026

Tenormin (atenolol): Clinical Trials Update, Market Analysis, and Projection

What is Tenormin and what market does it serve?

Tenormin is the branded formulation of atenolol, a cardioselective beta-1 adrenergic blocker used across hypertension and related cardiovascular indications. In practice, the brand competes primarily with multiple generic atenolol products and also faces channel-level substitution pressure from alternative beta blockers.

Primary commercial demand drivers

• Hypertension treatment in outpatient settings
• Cardiovascular risk management in patients where beta blocker therapy remains standard
• Ongoing use in patients already stabilized on atenolol (switch reluctance varies by payer and clinician preference)

Key pricing reality

• Branded prescription value for older, off-patent small molecules typically tracks to remaining exclusivity/contracting and then compresses materially after genericization. Tenormin is widely treated as a mature, generic-substituted product in most major markets.

---

What clinical trials update matters for Tenormin (atenolol)?

For a mature, off-patent beta blocker, “clinical trial updates” typically do not change the core labeling beyond new study endpoints, comparative effectiveness research, or guideline-adjacent evidence.

Trial activity pattern for atenolol

• Atenolol continues to appear in:
  • Comparative cardiovascular trials (beta blocker class comparisons or historical comparators)
  • Perioperative and cardioprotection contexts
  • Pharmacovigilance and real-world evidence cohorts
• These do not usually create new branded differentiation for Tenormin, but they shape guideline positioning for beta blockade in specific clinical pathways.

Regulatory relevance

• No widely recognized, brand-changing late-stage registration program is generally associated with Tenormin as a standalone branded asset.
• For business planning, the clinical “signal” is less about a near-term new phase 3 readout and more about whether evidence continues to support beta blocker selection for hypertension and cardiovascular risk scenarios versus competing agents.

Actionable takeaway

• Tenormin’s near-term commercial trajectory is governed by generic competition and payer contracting, not by a branded late-stage pipeline.

---

How does Tenormin’s competitive landscape look?

Competitive substitution occurs at three levels:

1. Within beta blockers: clinicians can select metoprolol, bisoprolol, carvedilol, nebivolol, or others depending on heart failure risk profiles, comorbidity patterns, and formulary tiers.
2. Within hypertension therapeutics: ACE inhibitors/ARBs, calcium channel blockers, and thiazide-like diuretics often dominate first-line choices.
3. Across generics: even when beta blockers are used, the market often prices at generic benchmarks.

Competitive implications for Tenormin

• Brand value is limited to remaining differentiation levers:
  • Formulation convenience (where applicable)
  • Channel contracts
  • Switch inertia in established patients

---

Where does atenolol fit in clinical guidelines and use patterns?

Atenolol remains a long-standing therapy for hypertension and cardiovascular indications, but its selection among beta blockers has varied by geography and guideline evolution.

Guideline dynamics relevant to market demand

• Beta blockers remain used in cardiovascular patients, especially post-event settings historically.
• Hypertension monotherapy choice increasingly centers on drug classes with stronger contemporary comparative evidence for hard outcomes in many guideline systems.
• In markets where beta blockers are not preferred first-line, atenolol demand is more likely to come from:
  • Patient continuity
  • Comorbidity-driven selection
  • Formulary placement rather than new starts

---

What market analysis supports a projection for Tenormin?

Because Tenormin is an established, off-patent beta blocker, the projection should be framed as a mature brand under generic substitution, where unit demand may stay stable but pricing erodes over time.

Market drivers and constraints

• Downward pricing pressure from generics
• Stable or slowly declining treated population in hypertension as formularies shift
• Share retention where:
  • payer formulary continues to list atenolol products at favorable tiers
  • clinicians continue prescribing for specific patient subgroups

Quantitative projection method (business model)

For mature generic-branded medicines, projection typically follows:

• Volume: function of underlying prevalence and continuity of use
• Net sales: function of net price after rebates/discounts and brand-vs-generic share
• Share shift: influenced by formulary placement and competitor beta blockers

Given Tenormin’s mature status and the general market behavior of off-patent beta blockers, the expected path is:

• Stable-to-declining branded net sales
• Volatility driven by country-specific contracting and supply/channel events

---

What does a realistic 3- to 5-year outlook look like?

Atenolol brands generally do not re-expand after genericization unless there is:

• new regulatory exclusivity,
• formulation/device patent protection,
• or evidence driving a guideline shift that improves new-start preference.

Base-case outlook for Tenormin branded sales

• Net sales trend: gradual decline or flattening with periodic discounting effects
• Volume trend: modest decline or stability with substitution trends
• Mix trend: shift toward cheaper generics over time in higher-access systems

This is consistent with how older cardiovascular generics typically behave under global substitution pressure.

---

What filings and regulatory signals should be tracked for Tenormin?

Even when late-stage trials do not exist, governance signals matter:

• Patent landscape changes for any residual brand-specific rights (formulation, manufacturing, packaging)
• Regulatory renewals that can influence availability and tender positioning
• Safety labeling updates that can affect prescribing behavior

For business monitoring, the focus is on:

• whether Tenormin maintains a reimbursement position
• whether any new formulation changes therapeutic substitution dynamics

---

Key Takeaways

• Tenormin is a mature branded atenolol product competing in a market dominated by generic substitution and class-level beta blocker alternatives.
• Clinical trial “updates” for atenolol tend to support evidence-based placement rather than drive new brand-changing registrations.
• The commercial outlook is primarily determined by payer contracting, formulary tiering, and generic share, not by near-term pipeline catalysts.
• Expected medium-term pattern is stable-to-declining branded net sales with limited upside unless a jurisdiction-specific exclusivity or contracting advantage persists.

---

FAQs

1) Does Tenormin have an active late-stage clinical pipeline that could restart growth?

No known brand-changing late-stage registration program is typically associated with atenolol brands in the current period; evidence updates tend to be incremental rather than catalytic.

2) What drives Tenormin demand versus other beta blockers?

Formulary placement, payer tiering, and patient continuity on existing beta blocker therapy.

3) Are hypertension guidelines shifting away from beta blockers, impacting Tenormin?

Many guideline systems increasingly deprioritize beta blockers for first-line hypertension, which can pressure new starts for atenolol relative to other classes.

4) How does generic competition affect Tenormin pricing?

Generic products compress net pricing and shift volume away from branded offerings over time, making branded growth hard to sustain.

5) What is the best operational metric to monitor for projection accuracy?

Branded net sales trend adjusted for contract structure, supported by share-of-therapeutic-class proxy measures and formulary tier changes by geography.

---

References

[1] U.S. Food and Drug Administration. Drug Trials Snapshots: Tenormin (atenolol). (FDA database). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] DailyMed. Tenormin (atenolol) prescribing information. https://dailymed.nlm.nih.gov/
[3] National Library of Medicine. ClinicalTrials.gov: Search results for atenolol. https://clinicaltrials.gov/
[4] World Health Organization. WHO Model Formulary / beta blockers therapeutic class references (context on class use and indications). https://www.who.int/teams/health-product-and-policy-standards/essential-medicines/